Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1CNS 1

Conditions

Thyroid Neoplasms 1Pheochromocytoma 1Paraganglioma 1Neuroendocrine Tumors 1Differentiated Thyroid Cancer 1

Interventions

3-Iodobenzylguanidine 5spartalizumab 1lutetium Lu 177 dotatate 1copper dotatate CU-64 1belzutifan 1Quality of Life 1Patient Reported Outcome Measures 1Nivolumab 1Molecular Diagnostic Techniques 1Melphalan 1Lutetium-177 1Lutetium 1Iodine-131 1Immunotherapy 1Everolimus 1Drug Therapy 1Biological Therapy 13-fluorobenzylguanidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Pheochromocytoma × Iodine-131 × Clear all
NCT00458952 2016-07-13

Phase 1 Study of Iobenguane (MIBG) I 131 in Patients With Malignant Pheochromocytoma/Paraganglioma

Molecular Insight Pharmaceuticals, Inc.

Phase 1/2 Completed
24 enrolled 8 charts
CNSEndocrineNET

Paraganglioma, Pheochromocytoma, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡